Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$1.59 - $3.85 $726 - $1,759
457 New
457 $1,000
Q2 2022

Aug 09, 2022

BUY
$5.86 - $13.23 $52 - $119
9 Added 75.0%
21 $0
Q1 2022

May 06, 2022

SELL
$10.92 - $16.41 $174 - $262
-16 Reduced 57.14%
12 $0
Q3 2021

Nov 12, 2021

BUY
$12.68 - $17.79 $126 - $177
10 Added 55.56%
28 $0
Q2 2021

Aug 09, 2021

SELL
$12.95 - $15.41 $103 - $123
-8 Reduced 30.77%
18 $0
Q1 2021

May 12, 2021

BUY
$14.42 - $21.39 $374 - $556
26 New
26 $0

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $115M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.